Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus

#1642

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.

Aim(s): This is a biological prospective trial (clinicaltrials.gov:NCT02305810) in 38 patients treated with RAD001 which aims to find soluble predictive factors.

Materials and methods: Blood tests to test circulating endothelial cells (CECs), circulating endothelial progenitor cells (CEPS), as well as soluble angiogenic factors - VEGF, bFGF and thrombospondin-1 (TSP-1) - have been collected at the baseline, after 1 and 3 months of treatment and at the progression.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: cella c

Authors: Cella C, Spada F, Labanca V, Radice D, Rubino M,

Keywords: pancreatic nets, biomarker, everolimus,